IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

BATT ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP04/006317

FILED: 11 JUNE 2004

U.S. APPLICATION NO: 10/560,352

35 USC §371 DATE: Herewith

FOR: 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS

Mail Stop: PCT

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SECONDARY PRELIMINARY AMENDMENT

Sir:

Prior to the examination of the above-referenced patent application, please enter the following preliminary amendments:

Amendments to the Specification begin on page 2 of this paper.

Remarks begin on page 3 of this paper.

FT 1 .

IAP13 Rec'd PCT/PTO 20 NOV 2006

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10							
<u>EV</u> 724615555US	November 20, 2006						
Express Mail Label Number	Date of Deposit						

(REV 10-96)			. Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER ON-4-33227A						
		TRANSMITTAL LETTER TO	THE UNITED STATES	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)						
		DESIGNATED/ELECTED C		10/560,352						
		CONCERNING A FILING UI	•							
		NATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED						
		P04/006317	11 June 2004 (11.06.04)	13 June 2006 (13.06.06)						
		OF INVENTION IOPYRIMIDINE DERIVATIVES AS R	AF KINASE INHIBITORS							
	APPLICANT(S) FOR DO/EO/US									
ВА	TTE	T AL.								
App	olicar	nt herewith submits to the United States E	Designated/Elected Office (DO/EO/US) the	ne following items and other information:						
1.		This is a FIRST submission of items cor		•						
2. 3.	A	 ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay 								
	_	examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).								
4.		A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.								
5.		 A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau). 								
		b. has been transmitted by the Inte	ernational Bureau. (See Form PCT/IB/30	08)						
6.		 c. is not required, as the application A translation of the International Application 	n was filed in the United States Receivin tion into English (35 U.S.C. 371(c)(2)).	g Office (RO/OS).						
7.		Amendments to the claims of the Interna	ational Application under PCT Article 19							
		a. are transmitted herewith (requireb. have been transmitted by the Int	ed only if not transmitted by the Internation ternational Bureau.	onal Bureau).						
		c. have not been made; however,	the time limit for making such amendmer	nts has NOT expired.						
8.	П	d. have not been made and will no A translation of the amendments to the	t be made. claims under PCT Article 19 (35 U.S.C. 3	371 (c)(3)).						
9.		An executed Declaration and Power of A	Attorney (original or copy) (35 U.S.C. 371	(c)(4)). ´´						
10.		A translation of the annexes to the Interest 371(c)(5)).	national Preliminary Examination Report	under PCT Article 36 (35 U.S.C.						
		in (chem)								
lter	ns 1	1. to 16. below concern document(s) o	r information included.							
11.		An Information Disclosure Statement un	der 37 CFR 1.97 and 1.98.							
12.		An assignment document for recording.	A separate cover sheet in compliance w	vith 37 CFR 3.28 and 3.31 is included.						
13.		A FIRST preliminary amendment. A SECOND or SUBSEQUENT prelimina	ary amendment.							
14.		An Application Data Sheet under 37 CF	R 1.76.							
15.		A substitute specification.								
16.		A change of power of attorney and/or ac	ddress letter.							
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.								
18.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).								
19.			translation of the International application	n under 35 U.S.C. 154(d)(4).						
20.	\boxtimes	Other items or information: postcard								

U.S. APPLICATION NO. 10/560,352					ON-4-332	DOCKET NUMBER					
	es are submitted:							CALCULATIONS PTO USE			
The following fees are submitted:						ONLY	4110	INS PTO USE			
21. Basic national fee											
22. Examinatio		/ examination	n report was prepared by	USP	ſΩ						
			T Article 33(1)-(4)				\$				
All of	ther situations						\$				
23. Search fee											
If Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$ If International Search Report was prepared and provided to the Office \$ All other situations											
								6	_		
Additional fee fo	or specification and d		F 21, 22 AND 23 = in paper over 100 sheet	s (excl	uding	a seau	ence listing	s or computer	0		
			e fee is \$250 for each ac								
Total Sheets			ach additional 50 or frac nd up to a whole number			RA	TE.				
- 100 =	/50 =				Х	\$	250	\$			
	30 for furnishing the earliest claimed price			0				\$	130		
CLAIMS		RFILED	NUMBER EXTRA	l		RAT	Ē	_			
Total claims		- 20 =		>	<	\$	50	\$			
Independent cla	ims	- 3 =		>	<u> </u>	\$	200	\$			
MULTIPLE DEP	PENDENT CLAIM(S)	(if applicable	2)	-	-	\$	360	\$			
			TOTAL OF ABOV	E C	ALC	ULAT	IONS =	\$			
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).						\$					
SUBTOTAL =						\$					
Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).							\$				
	· · · ·						L FEE =	\$		-	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						\$					
			TOTA	LFE	ES I	ENCL	OSED =	\$			
								Amoun be: refund		\$	
								char	ged	\$	
a. A chec	k in the amount of \$_		to cover the above	ees is	encl	losed.	•				
	<u> </u>										
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											
Send all correspondence to the address associated with Customer No. 001095, which is currently:											
Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 Kristin Konzak Attorney for Applicants Reg. No. 44,848 (617) 871-3216											